NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

HFE-Associated Hereditary Hemochromatosis

, MD, , MS, and , MD.

Author Information
, MD
Director, Center for Liver Disease
Virginia Mason Medical Center
Clinical Professor of Medicine
University of Washington
Seattle, Washington
, MS
Genetic Counselor, Clinic Manager, Medical Genetics
University of Washington
Seattle, Washington
, MD
Professor, Medicine and Genetics
University of Washington
Seattle, Washington

Initial Posting: ; Last Update: April 19, 2012.


Clinical characteristics.

HFE-associated hereditary hemochromatosis (HFE-HH) is characterized by inappropriately high absorption of iron by the gastrointestinal mucosa. The phenotypic spectrum of HFE-HH is now recognized to include:

  • Those with clinical HFE-HH, in which manifestations of end-organ damage secondary to iron storage are present;
  • Those with biochemical HFE-HH, in which the only evidence of iron overload is increased transferrin-iron saturation and increased serum ferritin concentration; and
  • Non-expressing p.Cys282Tyr homozygotes in whom neither clinical manifestations of HFE-HH nor iron overload are present.

Clinical HFE-HH is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and testes. In untreated individuals: early symptoms may include abdominal pain, weakness, lethargy, and weight loss; the risk of cirrhosis is significantly increased when the serum ferritin is higher than 1,000 ng/mL; other findings may include progressive increase in skin pigmentation, diabetes mellitus, congestive heart failure and/or arrhythmias, arthritis, and hypogonadism. Clinical HFE-HH is more common in men than women.


The diagnosis of clinical HFE-HH in individuals with clinical findings consistent with HFE-HH and the diagnosis of biochemical HFE-HH are typically based on finding elevated transferrin-iron saturation 45% or higher and serum ferritin concentration above the upper limit of normal (i.e.,>300 ng/mL in men and >200 ng/mL in women) and two HFE-HH-causing allelic varaints on confirmatory HFE molecular genetic testing. Although serum ferritin concentration may increase progressively over time in untreated individuals with HFE-HH, it is not specific for HFE-HH and, therefore, cannot be used alone for identification of individuals with HFE-HH.


Treatment of manifestations: Clinical HFE-HH: treatment by phlebotomy (removal of blood) to maintain serum ferritin concentration at or lower than 50 ng/mL. Biochemical HFE-HH: start phlebotomy when serum ferritin concentration is higher than 500 ng/mL. Non-expressing p.Cys282Tyr homozygotes: No need for phlebotomy, since these individuals do not have iron overload.

Prevention of secondary complications: Vaccination against hepatitis A and B.

Surveillance: Clinical HFE-HH: Once the serum ferritin concentration is lower than 50 ng/mL, routine monitoring of serum ferritin concentration every three to four months; routine screening for hepatocellular cancer (HCC) in individuals who have cirrhosis. Biochemical HFE-HH and non-expressing p.Cys282Tyr homozygotes: Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels.

Agents/circumstances to avoid: Medicinal iron, mineral supplements, excess vitamin C, and uncooked seafood; alcohol consumption in those with hepatic involvement.

Evaluation of relatives at risk: Offer molecular genetic testing to the adult sibs of a proband homozygous for p.Cys282Tyr to allow early diagnosis and surveillance.

Genetic counseling.

HFE-HH is inherited in an autosomal recessive manner.

Risk to sibs: When both parents of an affected individual are heterozygous for the HFE pathogenic variant, the risk to sibs of inheriting two HFE pathogenic variants is 25%. However, because the carrier frequency for a mutant HFE allele in persons of European origin is high (11% or 1/9), on occasion one parent of an affected individual has two abnormal HFE alleles. In such instances, the risk to each sib of inheriting two HFE pathogenic variants is 50%.

Risk to offspring: Offspring of an individual with HFE-HH inherit one mutant HFE allele from the affected parent. Because of the 1/9 chance that the other parent is a carrier for a mutant HFE allele, the risk to the offspring of inheriting two HFE pathogenic variants is approximately 5%.

Prenatal testing: Although prenatal testing would be technically feasible for pregnancies at 25% or more risk, such requests would be highly unusual because HFE-HH is an adult-onset, treatable disorder with low clinical penetrance.


The American Association for the Study of Liver Disease (AASLD) has recently published practice guidelines for diagnosis and management of hemochromatosis [Bacon et al 2011] (full text).

Clinical Diagnosis

It is increasingly unusual for individuals with HFE-associated hereditary hemochromatosis (HFE-HH) to present with advanced "clinical" HFE-HH (i.e., with end-organ damage secondary to iron storage). More typically, individuals with HFE-HH are determined to have "biochemical" HFE-HH (i.e., elevated serum TS and elevated serum ferritin concentration) after evaluation of transferrin-iron saturation and serum ferritin concentration reveals evidence of iron overload (see Testing). Occasionally, individuals with HFE-HH present either with early clinical findings of hereditary hemochromatosis such as elevated serum liver enzymes or vague nonspecific symptoms such as abdominal pain, fatigue, arthralgia, and/or decreased libido.

HFE-HH should be suspected in any individual with clinical signs of advanced iron overload, including:

  • Hepatomegaly
  • Hepatic cirrhosis
  • Hepatocellular carcinoma
  • Diabetes mellitus
  • Cardiomyopathy
  • Hypogonadism
  • Arthritis (especially involving the metacarpophalangeal joints)
  • Progressive increase in skin pigmentation


Biochemical Testing

Transferrin-iron saturation (TS) is an early and reliable indicator of risk for iron overload in HFE-HH; the TS is not age-related in adults and does not correlate with the presence or absence of clinical findings.

Approximately 80% of individuals with HFE-HH have had a fasting serum transferrin-iron saturation of at least 60% (men) or at least 50% (women) on two or more occasions in the absence of other known causes of elevated transferrin-iron saturation.

  • A screening study from Denmark of over 6,000 men showed that 89% of p.Cys282Tyr homozygotes had a serum TS higher than 50% [Pedersen & Milman 2009].
  • The Hemochromatosis and Iron-Overload Screening (HEIRS) study screened more than 100,000 persons in the US and Canada and found that 84% of male p.Cys282Tyr homozygotes had a serum TS higher than 50% and 73% of female p.Cys282Tyr homozygotes had a TS higher than 45% [Adams et al 2005].
  • Although homozygotes for p.Cys282Tyr may have a serum TS below 45% in early adulthood, they commonly develop an elevated serum TS over time [Olynyk et al 2004].

Serum ferritin concentration generally increases progressively over time in individuals with untreated clinical HFE-HH; however, an elevated serum ferritin concentration alone is not specific for iron overload as it is an acute phase reactant and may be caused by inflammatory or neoplastic disorders (especially when the serum TS is normal).

  • Commonly accepted ferritin values for the upper limit of normal (from the HEIRS study) are lower than 300 ng/mL in males and lower than 200 ng/mL in females [Adams et al 2005.
  • No “typical” range for ferritin values for persons with HFE-HH has been defined: it may range from normal to several thousand.

Note: McGrath et al [2002] developed a nomogram (see included figure) that allows prediction of genotype based on the pattern of serum iron studies.

Quantitative phlebotomy can be used to determine the quantity of iron that can be mobilized, thus confirming the diagnosis of HFE-HH in an individual with evidence of iron overload who is not a p.Cys282Tyr homozygote or a p.Cys282Tyr/p.His63Asp compound heterozygote and who is unable or unwilling to undergo liver biopsy. Note: The quantity of iron (in grams) mobilized is calculated by multiplying the number of phlebotomies times 0.25; most individuals fully expressing the phenotype have more than four grams of iron that can be mobilized.

Heterozygotes vs Homozygotes

Although a threshold serum TS of 45% may be more sensitive than the higher values used in the past for detecting HFE-HH, it may identify heterozygotes who are not at risk of developing clinical findings [McLaren et al 1998].

In the large study in Danish men, Pedersen & Milman [2009] showed that:

  • Among p.Cys282Tyr/wild type (wt) heterozygotes, 9% had elevated serum TS (≥50%), 9% had elevated ferritin (≥300 ng/mL), and 1.2% had elevation of both serum TS and ferritin.
  • Among p.His63Asp/wt heterozygotes, 8% had elevated serum TS, 12% had elevated ferritin, and 2% had elevation of both serum TS and ferritin.
  • No individuals with the p.Ser65Cys variant had elevation of both serum TS and ferritin.

Note: The abnormalities in iron studies observed in p.Cys282Tyr heterozygotes do not necessarily reflect a hemochromatosis-associated phenotype.

Histologic examination of liver tissue. Liver biopsy is useful to confirm hepatic iron overload, particularly in an individual with presumed HFE-HH who is not a p.Cys282Tyr homozygote or a p.Cys282Tyr/p.His63Asp compound heterozygote.

Testing on liver tissue should include measurement of hepatic iron concentration, calculation of hepatic iron index, and stains to assess pattern and severity of iron overload, as well as stains to determine the presence or absence of hepatitis and fibrosis.

  • The hepatic iron concentration (HIC) is determined in µmol/g of dry weight.
  • The hepatic iron index (HII) is then calculated by dividing the hepatic iron concentration by the age (in years) of the individual. Among individuals with HFE-HH who fully express the phenotype, 85%-90% have an HII of greater than 1.9.

    Note: (1) The HIC and HII were primarily used to differentiate presumed homozygotes from presumed heterozygotes prior to the era of HFE molecular genetic testing. (2) These histochemical tests are currently useful for diagnostic purposes when the diagnosis cannot be established by molecular genetic testing.
  • The degree of hepatic iron loading can also be semi-quantitatively assessed by histochemical techniques using Perls' Prussian blue stain (grade: 0-4; normal: 0-1; 3-4: typical for HFE-HH) [Scheuer 1973]. In HFE-HH, the greatest density of iron staining is in the periportal hepatocytes, with minimal or no iron staining in reticuloendothelial cells.

Note: Liver biopsy is usually not otherwise indicated for diagnostic purposes in HFE-HH but can be critical in establishing the presence or absence of cirrhosis, which influences prognosis (see Management, Evaluations Following Initial Diagnosis).

Magnetic resonance imaging (MRI) has the potential to estimate liver iron content by utilizing the paramagnetic properties of iron. In the past, routine MRI scanning lacked sensitivity to differentiate between various degrees of iron overload; however, a specialized MRI technique with excellent sensitivity for estimation of hepatic iron concentration has been approved by the FDA for clinical use [St Pierre et al 2005].

Molecular Genetic Testing

Gene. All individuals with HFE-HH have biallelic pathogenic variants in HFE.

Clinical testing

  • Targeted mutation analysis identifies the two most common disease-causing alleles in HFE (p.Cys282Tyr and p.His63Asp) [Feder et al 1996]. Approximately 87% of individuals of European origin with HFE-HH are either homozygous for the p.Cys282Tyr pathogenic variant or compound heterozygous for the p.Cys282Tyr and p.His63Asp pathogenic variants.

    Note: Most clinical laboratories do not routinely test for the p.Ser65Cys allele because it appears to account for only 1% of individuals affected clinically [Mura et al 1999] and its clinical significance is currently unclear.
  • Sequence analysis is used to identify other mutant alleles associated with HFE-HH [Barton et al 1999].

Table 1.

Summary of Molecular Genetic Testing Used in HFE-HH

Gene 1Test MethodMutations
Detected 2
Mutation Detection Frequency by Test Method 3
% of Individuals with HH 4, 5Genotype
HFETargeted mutation analysisp.Cys282Tyr, p.His63Asp~60%-90%p.[Cys282Tyr]+[Cys282Tyr]
~1%p.[His63Asp]+[His63Asp] 6
Sequence analysis 7Sequence variants 8UnknownUnknown 9
Deletion/duplication analysis 10Exon and whole-gene deletionsUnknownUnknown

See Table A. Genes and Databases for chromosome locus and protein name.


See Molecular Genetics for information on allelic variants.


The ability of the test method used to detect a mutation that is present in the indicated gene


In populations of European origin [Ramrakhiani & Bacon 1998]


Morrison et al [2003]


There is no evidence that p.[His63Asp]+[ His63Asp] is associated with a hemochromatosis phenotype in the absence of another cause of iron overload.


Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.


Includes the three variants included in targeted mutation analysis


A few individuals who are compound heterozygous for the p.Cys282Tyr allele and one of a small number of rare HFE pathogenic variants have the hemochromatosis phenotype.


Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; a variety of methods including quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), or targeted chromosomal microarray analysis (gene/segment-specific) may be used. A full chromosomal microarray analysis that detects deletions/duplications across the genome may also include this gene/segment.

Test characteristics. See Clinical Utility Gene Card [Stuhrmann et al 2010] for information on test characteristics including sensitivity and specificity.

Testing Strategy

To confirm/establish the diagnosis in an adult with transferrin-iron saturation higher than 45% (see Figure 1):

Figure 1.

Figure 1.

Testing strategy to establish the diagnosis of HFE-HH

  • First, perform targeted mutation analysis. Those homozygous for the p.Cys282Tyr pathogenic variant or compound heterozygous for the p.Cys282Tyr and p.His63Asp pathogenic variants have the genotype to develop HFE-HH.
  • For those individuals in whom only one p.Cys282Tyr pathogenic variant is identified, perform HFE sequence analysis and possibly deletion/duplication analysis.
  • Those with a second disease-causing HFE allele have the genotype to develop HFE-HH.
  • Those who do not have a second identifiable disease-causing HFE allele AND who are suspected of having HH (i.e., have elevated ferritin concentration and/or clinical manifestations of iron storage) warrant the following:

Predictive testing for at-risk asymptomatic adult family members requires prior identification of the pathogenic variants in the family.

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the pathogenic variants in the family.

Clinical Characteristics

Clinical Description

Three phenotypes of HFE-associated hereditary hemochromatosis (HFE-HH) are now recognized:

  • Clinical HFE-HH (individuals with end-organ damage [e.g., advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes] secondary to iron storage)
  • Biochemical HFE-HH (individuals with evidence of iron overload as determined by transferrin-iron saturation and serum ferritin concentration only)
  • Non-expressing p.Cys282Tyr homozygotes (p.Cys282Tyr homozygotes without clinical or biochemical evidence of iron overload [i.e., normal serum ferritin concentration])

Individuals with HFE-HH may be identified because of signs and symptoms related to iron overload (i.e., clinical HFE-HH); however, most frequently they are identified before symptoms develop, either through detection of abnormal iron-related studies (i.e., biochemical HFE-HH) or by molecular genetic testing used in the evaluation as family members at risk for HFE-HH (non-expressing p.Cys282Tyr homozygotes).

The difference between clinical HFE-HH and biochemical HFE-HH must be understood in the interpretation of population studies evaluating morbidity related to HH. Several large-scale screening studies in the general population have demonstrated that most individuals homozygous for the p.Cys282Tyr pathogenic variant do not have clinical HFE-HH; however, a significant proportion of individuals with this genotype (especially males) have biochemical HFE-HH.

Although early reports have suggested that males are ten times more likely than females to have symptoms of organ failure resulting from HFE-HH, subsequent studies showed that among individuals with HFE-HH males are twice as likely as women to develop complications of end-stage organ failure [Moirand et al 1997].

When identified through iron studies or screening of at-risk family members, 75%-90% of individuals with HFE-HH are asymptomatic. Normal serum ferritin concentration at diagnosis is usually associated with lack of symptom development [Yamashita & Adams 2003]. Clinical disease appears to be more common among at-risk sibs of clinically affected individuals.

Clinical HFE-HH

Individuals with clinical HFE-HH have inappropriately high absorption of iron from a normal diet by the gastrointestinal mucosa, resulting in excessive parenchymal storage of iron, which may result in damage in a number of end-organs and, potentially, organ failure.

Symptoms related to iron overload usually appear between age 40 and 60 years in males and after menopause in females. Occasionally, HFE-HH manifests at an earlier age, but hepatic fibrosis or cirrhosis is rare before age 40 years.

Often the first signs of clinical HFE-HH are arthropathy (joint stiffness and pain) involving the metacarpophalangeal joints, progressive increase in skin pigmentation resulting from deposits of melanin and iron, diabetes mellitus resulting from pancreatic iron deposits, and cardiomyopathy resulting from cardiac parenchymal iron stores. Hepatomegaly may or may not be present early in the disease; however, asymptomatic individuals can occasionally have hepatomegaly on physical examination. Males may have impotence from pituitary dysfunction. Abdominal pain, weakness, lethargy, and weight loss are common, but nonspecific, findings.

Alcohol consumption worsens the symptoms in HFE-HH [Scotet et al 2003].

With progression of the disease, liver cirrhosis may develop and be complicated by portal hypertension, hepatocellular carcinoma, and end-stage liver disease [Kowdley et al 2005]. The HEIRS study found an odds ratio of 3.3 for liver disease among p.Cys282Tyr homozygous men [Adams et al 2005]. In addition, cirrhosis is much more common among p.Cys282Tyr homozygotes who consume more than 60 g of alcohol per day compared to those who drink less [Fletcher et al 2002].

By the time cirrhosis or liver failure is recognized, approximately 50% of individuals have diabetes mellitus and 15% have congestive heart failure or arrhythmias.

Individuals diagnosed and treated prior to the development of cirrhosis appear to have normal life expectancy; those identified after the development of cirrhosis have a decreased life expectancy even with iron depletion therapy [Adams et al 2005].

Individuals with cirrhosis who are treated have a better outcome than those who are not; however, treatment does not eliminate the 10%-30% risk for hepatocellular carcinoma (HCC) and cholangiocarcinoma years after successful iron depletion.

Failure to deplete iron stores after 18 months of treatment is a poor prognostic sign. With iron depletion, dysfunction of some affected organs (liver and heart) can improve; however, endocrine abnormalities and arthropathy improve in only 20% of those treated.

Death in individuals with clinical HFE-HH is usually caused by liver failure, cancer, congestive heart failure, or arrhythmia.

Biochemical HFE-HH

Controversy exists among experts as to whether individuals who have biochemical HFE-HH in the absence of clinical HFE-HH are at increased risk for development of complications of iron overload and whether they are candidates for phlebotomy treatment (see Management).

Prospective follow-up of a few individuals in some of these studies has been inconclusive as to whether iron overload is progressive. The evidence at present suggests that although serum ferritin concentration may rise in these individuals over time, end-organ damage is uncommon but is more frequently observed in male p.Cys282Tyr homozygotes than female p.Cys282Tyr homozygotes [see Yamashita & Adams 2003, Andersen et al 2004, Olynyk et al 2004, Allen et al 2008, Gurrin et al 2008].

Non-Expressing p.Cys282Tyr Homozygotes

Three recent longitudinal population-based screening studies showed that 38%-50% of p.Cys282Tyr homozygotes may develop iron overload (i.e., elevated serum ferritin concentration) and 10%-33% may eventually develop hemochromatosis-related symptoms (i.e., nonspecific symptoms that may include fatigue and arthralgia) or end-organ damage (e.g., diabetes mellitus, cirrhosis, and/or cardiomyopathy); the vast majority developing end-organ damage are male [European Association for the Study of the Liver 2010].

It is estimated that 38%-50% of p.Cys282Tyr homozygotes may develop iron overload, and 10%-33% may develop clinical features [Whitlock et al 2006]. The proportion of p.Cys282Tyr homozygotes with iron overload-related disease is substantially higher for men than for women (28% vs. 1%) [Allen et al 2008].

Therefore, although “non-expressing homozygotes” are unlikely to develop end-organ damage over time, a substantial proportion of male p.Cys282Tyr homozygotes may develop progressive iron overload or symptoms of iron overload [Yamashita & Adams 2003, Gurrin et al 2008, Gurrin et al 2009, Allen et al 2010, Gan et al 2011].


Although some individuals who are heterozygous for an HFE pathogenic variant tend to have elevated serum TS and ferritin concentrations that exceed normal, they do not develop complications of iron overload [Bulaj et al 1996, Allen et al 2008]. See Diagnosis, Heterozygotes vs Homozygotes.

Genotype-Phenotype Correlations

Homozygotes for p.Cys282Tyr are at a greater risk for iron overload than p.Cys282Tyr/p.His63Asp compound heterozygotes.


Penetrance in HFE-HH refers to the percentage of adults (males and females separately) homozygous or compound heterozygous for HFE pathogenic variants who exhibit either clinical HFE-HH or biochemical HFE-HH:

  • p.Cys282Tyr homozygotes. Penetrance for biochemically defined iron overload among p.Cys282Tyr homozygotes is relatively high, but not 100%. In contrast, accumulating data suggest that penetrance for the clinically defined iron overload is quite low. In the absence of unbiased data, penetrance of clinical endpoints of iron overload cannot yet be determined for individuals homozygous for p.Cys282Tyr; however, penetrance was as low as 2% in the large study by Beutler et al [2002]. Currently, no test can predict whether an individual homozygous for p.Cys282Tyr will develop clinical HFE-HH.
  • p.Cys282Tyr/p.His63Asp compound heterozygotes. The penetrance for this genotype is low: only approximately 0.5%-2.0% of such individuals develop clinical evidence of iron overload [Gurrin et al 2009].
  • Many p.Cys282Tyr/p.His63Asp compound heterozygotes who develop clinical evidence of iron overload appear to have a complicating factor (e.g., fatty liver, viral hepatitis) that leads to iron overload.

    Male p.Cys282Tyr/p.His63Asp compound heterozygotes also were more likely to report a history of liver disease in the HEIRS study (odds ratio 1.7 p=0.05) [Adams et al 2005].
  • p.His63Asp homozygotes. The penetrance for this genotype is even lower than the penetrance of the p.[Cys282Tyr]+[His63Asp] genotype. Although biochemically defined abnormalities may be present, characteristic clinical manifestations are rare [Gochee et al 2002].


HFE-HH has been variably described in the past as hereditary hemochromatosis, primary hemochromatosis, genetic hemochromatosis, and "bronze diabetes."

More recently, after the identification of other forms of iron overload associated with mutation of other iron-related genes, HFE-HH has been described as HFE-hemochromatosis or type 1 hemochromatosis.


The prevalence of individuals homozygous for the variant p.Cys282Tyr is approximately 3:1000 to 5:1000, or 1:200 to 1:400 [Adams et al 2005]:

  • The frequency of homozygotes among African Americans is rare (1:7000) with 2.3% of that population being heterozygotes.
  • Homozygosity for the p.Cys282Tyr variant is extremely rare among Asians; heterozygotes have a frequency of only approximately 1:1000.
  • Hispanics have homozygote and heterozygote frequencies of 0.027% and 3.0%, respectively.

The p.His63Asp variant rarely causes clinical problems in the homozygous or compound heterozygous (p.[Cys282Tyr]+[His63Asp]) state and is relatively common in the heterozygous state in most populations (northern Europeans: 25%; Hispanics: 18%; African Americans: 6%; Asians: 8.5%).

Considering the high frequency of heterozygotes for the p.Cys282Tyr and p.His63Asp alleles, approximately one third of the northern European population is heterozygous for either one or the other of these two variant alleles.

Differential Diagnosis

HFE-associated hereditary hemochromatosis (HFE-HH) (sometimes called type 1 HH) needs to be distinguished from several much rarer primary iron overload disorders as well as from secondary iron overload disorders.

Primary overload disorders are characterized by increased absorption of iron from a normal diet:

  • Juvenile hereditary hemochromatosis (sometimes called type 2 HH) has an earlier age of onset and more severe clinical manifestations than type 1 HH. Hepatocellular cancer has not been reported, possibly because of the short life span in this disorder. Causative allelic variants have been identified in two genes, giving rise to two clinically indistinguishable "subtypes": Type 2A, caused by mutation of HJV encoding hemojuvelin; and Type 2B, caused by mutation of HAMP. Inheritance is autosomal recessive [Roetto et al 1999, Camaschella et al 2000, De Gobbi et al 2002].
  • TFR2-related hereditary hemochromatosis (sometimes called type 3 HH) has a similar presentation to HFE-HH. Age of onset is earlier and progression is slower than in juvenile HH. It is caused by mutation of TFR2, which encodes transferrin receptor 2. TFR2-related hereditary hemochromatosis is rare; it has primarily been reported in Italy. Inheritance is autosomal recessive [Mattman et al 2002].
  • Ferroportin (SLC40A1)-related iron overload (ferroportin disease, type 4 hemochromatosis, HFE4) is also a disorder of iron overload, but unlike juvenile and HFE-HH, macrophages are iron laden. Onset is late and, in contrast to all other varieties of hemochromatosis, iron storage affects reticuloendothelial rather than parenchymal cells [Montosi et al 2001, Njajou et al 2001]. HFE4 presents in adulthood. It is caused by mutation of SLC40A1, which encodes ferroportin. Inheritance is autosomal dominant.
  • African iron overload results from a predisposition to iron overload that is exacerbated by excessive intake of dietary iron. It is particularly prevalent among Africans who drink a traditional beer brewed in non-galvanized steel drums. Mutation of other yet-to-be-defined iron-related genes predisposes to this condition. A specific pathogenic variant (p.Gln248His) in SLC40A1 [NM_014585.5] encoding ferroportin has been associated with tendency to iron overload in Africans and African Americans [McNamara et al 2005, Rivers et al 2007].
  • Neonatal hemochromatosis is a severe, often fatal iron overload syndrome that usually presents at birth. Iron overload occurs in utero. Inheritance is unknown, but autosomal recessive and mitochondrial inheritance have been postulated. No locus has been identified. A recent paper suggests that mutation of DGUOK, the gene which encodes deoxyguanosine kinase, may lead to a phenotype resembling this condition [Pronicka et al 2011]. See DGUOK-Related Mitochondrial DNA Depletion Syndrome, Hepatocerebral Form.

Secondary iron overload disorders

  • Liver diseases associated with parenchymal liver disease include conditions such as alcoholic liver disease, acute viral hepatitis or chronic hepatitis C, neoplasms, porphyria cutanea tarda, and inflammatory disorders, such as rheumatoid arthritis.
  • A very common liver disease, nonalcoholic fatty liver disease (NAFLD) may frequently lead to elevated serum ferritin level and may be associated with increased hepatic iron deposition [Nelson et al 2011, Kowdley et al 2012].
  • Iron overload can result from ingested iron in foods, cooking ware, and medicines, as well as parenteral iron from iron injections or transfusions for a chronic anemia such as beta-thalassemia or sickle cell disease.


The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis and management of hemochromatosis [Bacon et al 2011] (full text). The European Association for the Study of the Liver (EASL) published Clinical Practice Guidelines on the Management of hemochromatosis [European Association for the Study of the Liver 2010] (full text).

Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with HFE-associated hereditary hemochromatosis (HFE-HH), the following evaluations are recommended at initial diagnosis:

  • Serum ferritin concentration to establish disease status and prognosis (see Figure 2).
  • For p.Cys282Tyr homozygotes:
    • Liver biopsy is recommended for those with serum ferritin higher than 1,000 ng/mL or elevated AST and ALT to evaluate for advanced hepatic fibrosis [Morrison et al 2003, Bacon et al 2011].
    • Liver biopsy is not recommended for those with serum ferritin concentration lower than 1,000 ng/mL and normal ALT and AST because their risk for advanced hepatic fibrosis is low [Bacon et al 2011].
  • MRI to estimate parenchymal iron content by utilizing the paramagnetic properties of iron:
Figure 2.

Figure 2.

(LFT = Liver function tests) Use of serum ferritin concentration to help direct management

Treatment of Manifestations

The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis and management of hemochromatosis [Bacon et al 2011] (full text). The European Association for the Study of the Liver (EASL) published Clinical Practice Guidelines on the Management of hemochromatosis [European Association for the Study of the Liver 2010] (full text).

Clinical HFE-HH

Therapeutic phlebotomy is indicated in the presence of symptoms of iron overload or evidence of end-organ damage (e.g., advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes):

  • Periodic phlebotomy is a simple, inexpensive, safe, and effective treatment.
    • Each unit of blood (400-500 mL) with a hematocrit of 40% contains approximately 160-200 mg of iron.
    • Each mL of packed red blood cells contains 1 mg of iron.
  • The usual therapy is removal of the excess iron by weekly phlebotomy (i.e., removal of a unit of blood) until the serum ferritin concentration is 50 ng/mL or lower. Twice-weekly phlebotomy may be occasionally useful to accelerate iron depletion.
  • Weekly phlebotomy is carried out until the hematocrit is 75% of the baseline hematocrit.
  • At this point, if the serum ferritin concentration is 50 ng/mL or higher despite a significant reduction in hematocrit, the interval at which phlebotomy is performed needs to be spaced further apart. Once the serum ferritin concentration is 100 ng/mL or lower, serum ferritin concentration should be quantified in all affected individuals after each additional one or two treatments [Barton et al 1998].
  • The serum ferritin concentration is the most reliable and inexpensive way to monitor therapeutic phlebotomy.
  • Maintenance therapy is aimed at maintaining serum ferritin concentration below 50 ng/mL and transferrin-iron saturation below 50%. On average, men require removal of twice as many units of blood as women. Subsequent phlebotomies to prevent reaccumulation of iron can be carried out approximately every three to four months for men and once or twice a year for women.
  • Iron chelation therapy is not recommended unless an individual has an elevated serum ferritin concentration and concomitant anemia that makes therapeutic phlebotomy impossible. However, this is uncommon in individuals with HFE-HH.

Orthotopic liver transplantation is the only treatment for end-stage liver disease from decompensated cirrhosis. However, the post-transplant survival among untreated individuals with HFE-HH is poor [Crawford et al 2004, Kowdley et al 2005]. Although a recent study suggested that outcomes may have improved, this report did not enroll persons with documented HFE-HH but rather used a database [Yu & Ioannou 2007].

Biochemical HFE-HH

Both the EASL and AASLD guidelines now recommend therapeutic phlebotomy for persons with biochemical HFE-HH (i.e., those who have increased body iron stores in the absence of clinical evidence of iron overload). See European Association for the Study of the Liver [2010] (full text) and Bacon et al [2011] (full text). The exact serum ferritin concentration at which therapeutic phlebotomy should be initiated is not clear, the European Association for Study of Liver suggests performing phlebotomy once serum ferritin concentration is higher than 500 ng/mL.

Non-Expressing p.Cys282Tyr Homozygotes

These individuals do not have iron overload and thus do not need phlebotomy.

Prevention of Primary Manifestations

See Treatment of Manifestations.

Prevention of Secondary Complications

Individuals with iron overload should be advised against ingestion of shellfish or raw fish.

Vaccination against hepatitis A and B is advised [Tavill 2001].


Clinical HFE-HH

Once the serum ferritin concentration is lower than 50 ng/mL, monitor serum ferritin concentration every three to four months.

It is reasonable to perform follow-up T2* MRI for assessment of cardiac iron among persons with a history of cardiac involvement or known cardiac iron deposition.

Individuals who have cirrhosis should undergo routine screening for hepatocellular cancer (HCC) [Tavill 2001]. The AASLD Practice Guidelines on hepatocellular carcinoma advocate biannual abdominal imaging [Sherman 2010].

Note: The AASLD Guidelines recommend that individuals with cirrhosis undergo surveillance regardless of whether or not they have been iron depleted [Bacon et al 2011] (full text).

Biochemical HFE-HH

Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels [European Association for the Study of the Liver 2010] (full text).

Non-Expressing p.Cys282Tyr Homozygotes

Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels [European Association for the Study of the Liver 2010].

Agents/Circumstances to Avoid

Avoid the following:

  • Medicinal iron, mineral supplements, excess vitamin C, and uncooked seafood
  • Alcohol consumption in those with hepatic involvement

Evaluation of Relatives at Risk

In adults. The following strategy is appropriate:


Offer molecular genetic testing to the adult sibs of an individual homozygous for p.Cys282Tyr.


Perform iron studies (i.e., transferrin iron saturation and serum concentration of ferritin) on those sibs who are homozygous for p.Cys282Tyr.


Begin phlebotomy therapy if serum ferritin concentration is elevated above the upper limits of normal and if the proband has clinical HFE-HH. Note: Sibs of probands with clinical HFE-HH appear to have a higher prevalence of clinical HFE-HH than asymptomatic individuals detected through screening programs.

During childhood. No guidelines exist; however, screening in this age group is not advised because expression of symptomatic disease is rare.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

The oral iron chelator, deferasirox (Exjade®) has been studied in a Phase I/II study in patients with hemochromatosis [Phatak et al 2010].

Search for access to information on clinical studies for a wide range of diseases and conditions.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

HFE-associated hereditary hemochromatosis (HFE-HH) is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

  • Most parents of individuals with HFE-HH are heterozygotes and, therefore, carry a single copy of the HFE pathogenic allelic variant. Heterozygotes do not develop iron overload but may occasionally have abnormal serum iron studies [Bulaj et al 1996]. (See Diagnosis, Heterozygotes vs. Homozygotes and Clinical Description, Heterozygotes).
  • On occasion, one parent who has two variant HFE alleles may have clinical HFE-HH (i.e., presence of significant end-organ damage including advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes). The occurrence of an autosomal recessive disorder in two generations of a family without consanguinity (called "pseudodominance") is attributed to the high carrier frequency for a mutant HFE allele in persons of European origin (11% of the population or 1 in every 9 persons). Thus, it is appropriate to evaluate the parents of an individual with HFE-HH by molecular genetic testing if two variant HFE alleles have been identified or by serum iron studies (i.e., transferrin iron saturation and serum concentration of ferritin) if two abnormal alleles have not been identified.

Sibs of a proband

  • When both parents are heterozygous, each sib of an individual with HFE-HH has, at conception, a 25% chance of inheriting both mutated HFE alleles, a 50% chance of inheriting one mutated HFE allele, and a 25% chance of inheriting both normal HFE alleles.
  • When one parent of an individual with HFE-HH has HFE-HH because of homozygosity for p.Cys282Tyr and the other parent is a heterozygote, each sib of an individual with HFE-HH has a 50% chance of inheriting both mutated HFE alleles and a 50% chance of inheriting one mutated HFE allele.

Offspring of a proband

  • Individuals with clinical HFE-HH or biochemical HFE-HH (i.e., elevated serum TS and elevated serum ferritin concentration) are usually fertile. The offspring of an individual with HFE-HH are obligate heterozygotes (carriers) for a pathogenic variant.
  • Because of the high carrier rate for HFE mutant alleles in the general northern European population, the risk that a northern European reproductive partner of an individual with HFE-HH is heterozygous for the p.Cys282Tyr allele is approximately 1/9. Thus, the risk to the offspring of a proband of being homozygous for this allele is approximately 5% (i.e., 1/9 x 1/2 = 1/18). Molecular genetic testing can be offered to the reproductive partner of a person with HFE-HH to determine if their offspring are at risk of having a genotype with the potential for HFE-HH manifestations.
  • It is appropriate to evaluate adult offspring with molecular genetic testing and to proceed with serum iron studies (i.e., transferrin iron saturation and serum concentration of ferritin) if two abnormal disease-causing alleles are present.

Other family members of a proband. Each sib of the proband's parents is at a 50% risk of being a carrier.

Carrier Detection

If both HFE alleles have been identified in an affected family member, molecular genetic testing can be used to determine the carrier status of at-risk family members.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Testing of at-risk asymptomatic adults. Evaluation of sibs and offspring of affected individuals can be either by biochemical phenotype (i.e., serum iron studies) or by genotype (i.e., HFE molecular genetic testing) if the two abnormal alleles have been identified in the proband.

Genotype-based testing has been found to be cost-effective in most individuals because it has excellent negative predictive value. However, genotype-based testing has a low positive predictive value because many individuals who are p.Cys282Tyr homozygotes and compound heterozygotes will not express the disease [El-Serag et al 2000, Beutler et al 2002].

Testing of at-risk asymptomatic individuals younger than age 18 years. Consensus holds that individuals younger than age 18 years at risk for adult-onset disorders should not have testing in the absence of symptoms. See the National Society of Genetic Counselors position statement on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics policy statement: ethical and policy issues in genetic testing and screening of children.

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers or affected.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Population Screening

Population screening has been considered because of the high prevalence of HFE-HH, the lack of clinical findings early in the course of the disease, the lack of specificity of clinical findings once they appear, the low cost of diagnosis, the relatively simple and effective early treatment, and the high cost and low success rate of treatment when the diagnosis is established late.

Genotype-based population screening of HFE-HH is not recommended because penetrance appears to be low and the natural history of untreated individuals cannot be predicted. See European Association for the Study of the Liver [2010] (full text) and Bacon et al [2011] (full text).

Biochemical-based screening (using the serum iron markers transferrin iron saturation and serum concentration of ferritin) should be considered especially among men over age 30 years who are of northern European descent [Phatak et al 2008, European Association for the Study of the Liver 2010, Bacon et al 2011].

Prenatal Testing

While prenatal diagnosis for pregnancies at increased risk for HFE-HH is rarely requested, it may be available from laboratories offering testing for HFE or custom prenatal testing. The HFE pathogenic variants must be identified in an affected family member or both parents before prenatal testing can be performed.

Requests for prenatal testing for adult-onset conditions which (like HFE-HH) do not affect intellect or life span and have treatment available are very uncommon. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the pathogenic variants have been identified.


GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

HFE-Associated Hereditary Hemochromatosis: Genes and Databases

Data are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B.

OMIM Entries for HFE-Associated Hereditary Hemochromatosis (View All in OMIM)


Gene structure. HFE is approximately 13 kb in size and comprises seven exons [Feder et al 1996, Albig et al 1998]; HFE gives rise to at least eleven alternative transcripts encoding four to seven exons. For a detailed summary of gene and protein information, see Table A, Gene Symbol.

Pathogenic allelic variants. At least 28 distinct pathogenic variants have been reported; most are missense or nonsense mutations. Two missense mutations account for the vast majority of disease-causing alleles in the population:

  • p.Cys282Tyr removes a highly conserved cysteine residue that normally forms an intermolecular disulfide bond with beta-2-microglobulin, and thereby prevents the protein from being expressed on the cell surface.
  • p.His63Asp may alter a pH-dependent intramolecular salt bridge, possibly affecting interaction of the HFE protein with the transferrin receptor.

Table 2.

Selected HFE Pathogenic Allelic Variants

DNA Nucleotide ChangeProtein Amino Acid ChangeReference Sequences

Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.

Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​ See Quick Reference for an explanation of nomenclature.

Normal gene product. The largest predicted primary translation product is 348 amino acids, which gives rise to a mature protein of approximately 321 amino acids after cleavage of the signal sequence. The HFE protein is similar to HLA Class I molecules at the level of the primary structure [Feder et al 1996] and tertiary structure [Lebrón et al 1998]. The mature protein is expressed on the cell surface as a heterodimer with beta-2-microglobulin, and this interaction is necessary for normal presentation on the cell surface. The normal HFE protein binds to transferrin receptor 1 on the cell surface and may reduce cellular iron uptake; however, the exact means by which the HFE protein regulates iron uptake is as yet unclear [Fleming et al 2004].

Abnormal gene product. The p.Cys282Tyr pathogenic variant destroys a key cysteine residue that is required for disulfide bonding with beta-2-microglobulin. As a result, the HFE protein does not mature properly and becomes trapped in the endoplasmic reticulum and Golgi apparatus, leading to decreased cell-surface expression. The mechanistic basis for the phenotypic effect of other HFE pathogenic variants is not clear at present.


Published Guidelines/Consensus Statements

  1. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Available online. 2011. Accessed 4-8-15.
  2. Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available online. 2013. Accessed 4-8-15. [PubMed: 23428972]
  3. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. Available online. 2010. Accessed 4-8-15.
  4. National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available online. 2012. Accessed 4-8-15.

Literature Cited

  1. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769–78. [PubMed: 15858186]
  2. Albig W, Drabent B, Burmester N, Bode C, Doenecke D. The haemochromatosis candidate gene HFE (HLA-H) of man and mouse is located in syntenic regions within the histone gene cluster. J Cell Biochem. 1998;69:117–26. [PubMed: 9548560]
  3. Allen KJ, Bertalli NA, Osborne NJ, Constantine CC, Delatycki MB, Nisselle AE, Nicoll AJ, Gertig DM, McLaren CE, Giles GG, Hopper JL, Anderson GJ, Olynyk JK, Powell LW, Gurrin LC. HealthIron Study Investigators. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology. 2010;52:925–33. [PMC free article: PMC2932765] [PubMed: 20583211]
  4. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–30. [PubMed: 18199861]
  5. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914–9. [PubMed: 15070663]
  6. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS., American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328–43. [PMC free article: PMC3149125] [PubMed: 21452290]
  7. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ, Cook JD, Kowdley KV. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med. 1998;129:932–9. [PubMed: 9867745]
  8. Barton JC, Sawada-Hirai R, Rothenberg BE, Acton RT. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis. 1999;25:147–55. [PubMed: 10575540]
  9. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211–8. [PubMed: 11812557]
  10. Brittenham GM, Badman DG., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101:15–9. [PubMed: 12393526]
  11. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799–805. [PubMed: 8943161]
  12. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14–5. [PubMed: 10802645]
  13. Cheong B, Huber S, Muthupillai R, Flamm SD. Evaluation of myocardial ironoverload by T2* cardiovascular magnetic resonance imaging. Tex Heart Inst J. 2005;32:448–9. [PMC free article: PMC1336733] [PubMed: 16392242]
  14. Crawford DH, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, Jeffrey GP, McCaughan GW, Kerlin P, Powell LW, Elias EE. Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology. 2004;39:1655–62. [PubMed: 15185307]
  15. De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, Politou M, Lockitch G, Girelli D, Fargion S, Cox TM, Gasparini P, Cazzola M, Camaschella C. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973–9. [PubMed: 12060140]
  16. DuBois S, Kowdley KV. Review article: targeted screening for hereditary haemochromatosis in high-risk groups. Aliment Pharmacol Ther. 2004;20:1–14. [PubMed: 15225165]
  17. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med. 2000;132:261–9. [PubMed: 10681280]
  18. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53:3–22. [PubMed: 20471131]
  19. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408. [PubMed: 8696333]
  20. Fischer R, Harmatz P. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009;2009:215–21. [PubMed: 20008201]
  21. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis. 2004;8:755–73. [PubMed: 15464654]
  22. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281–9. [PubMed: 11832443]
  23. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. Semin Liver Dis. 2011;31:293–301. [PubMed: 21901659]
  24. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002;122:646–51. [PubMed: 11874997]
  25. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Nicoll AJ, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ. HealthIron Study Investigators. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-relatedmorbidity. Hepatology. 2009;50:94–101. [PMC free article: PMC3763940] [PubMed: 19554541]
  26. Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, Delatycki MB, Southey MC, Hopper JL, Giles GG, Anderson GJ, Olynyk JK, Powell LW, Allen KJ. HealthIron Study Investigators. The natural history of serum ironindices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008;135:1945–52. [PubMed: 18848943]
  27. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe EB, Gordon F, Polissar N. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129:494–503. [PubMed: 16083706]
  28. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE., NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77–85. [PMC free article: PMC3245347] [PubMed: 21953442]
  29. Lebrón JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93:111–23. [PubMed: 9546397]
  30. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood. 2002;100:1075–7. [PubMed: 12130528]
  31. McGrath JS, Deugnier Y, Moirand R, Jouanolle AM, Chakrabarti S, Adams PC. A nomogram to predict C282Y hemochromatosis. J Lab Clin Med. 2002;140:6–8. [PubMed: 12080322]
  32. McLaren CE, McLachlan GJ, Halliday JW, Webb SI, Leggett BA, Jazwinska EC, Crawford DH, Gordeuk VR, McLaren GD, Powell LW. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology. 1998;114:543–9. [PubMed: 9496946]
  33. McNamara L, Gordeuk VR, MacPhail AP. Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol. 2005;20:1855–8. [PubMed: 16336444]
  34. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med. 1997;127:105–10. [PubMed: 9229998]
  35. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001;108:619–23. [PMC free article: PMC209405] [PubMed: 11518736]
  36. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627–33. [PubMed: 12693884]
  37. Morrison ED, Kowdley K. Genetic liver disease in adults. Early recognition of the three most common causes. Postgrad Med. 2000;107:147–52. [PubMed: 10689414]
  38. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999;93:2502–5. [PubMed: 10194428]
  39. Nelson JE, Kowdley KV. Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management. Curr Gastroenterol Rep. 2005;7:71–80. [PubMed: 15701302]
  40. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV., Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448–57. [PMC free article: PMC3058264] [PubMed: 21274866]
  41. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, Snijders PJ, Rutten WP, Sandkuijl LA, Oostra BA, van Duijn CM, Heutink P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28:213–4. [PubMed: 11431687]
  42. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004;79:309–13. [PubMed: 15008603]
  43. Pedersen P, Milman N. Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Ann Hematol. 2009;88:775–84. [PubMed: 19159930]
  44. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med. 2008;149:270–2. [PubMed: 18711158]
  45. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010;52:1671–79. [PMC free article: PMC3034044] [PubMed: 20814896]
  46. Pronicka E, Węglewska-Jurkiewicz A, Taybert J, Pronicki M, Szymańska-Dębińska T, Karkucińska-Więckowska A, Jakóbkiewicz-Banecka J, Kowalski P, Piekutowska-Abramczuk D, Pajdowska M, Socha P, Sykut-Cegielska J, Węgrzyn G. Post mortem identification of deoxyguanosine kinase (DGUOK) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure. J Appl Genet. 2011;52:61–6. [PMC free article: PMC3026684] [PubMed: 21107780]
  47. Ptaszek LM, Price ET, Hu MY, Yang PC. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:689–92. [PubMed: 16136860]
  48. Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, Luciani A, Midiri M, Sallustio G, Valeri G, Caruso V, Centra M, Cianciulli P, De Sanctis V, Maggio A, Lombardi M. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009;30:62–8. [PubMed: 19557847]
  49. Ramrakhiani S, Bacon BR. Hemochromatosis: advances in molecular genetics and clinical diagnosis. J Clin Gastroenterol. 1998;27:41–6. [PubMed: 9706768]
  50. Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, Press RD, Adams PC, McLaren GD, Dawkins FW, McLaren CE, Reboussin DM. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007;38:247–52. [PMC free article: PMC3727273] [PubMed: 17276706]
  51. Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G, Carella M, Zelante L, Kelly AL, Cox TM, Gasparini P, Camaschella C. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet. 1999;64:1388–93. [PMC free article: PMC1377875] [PubMed: 10205270]
  52. Scheuer PJ. Disturbances of copper and iron metabolism. In: Liver Biopsy Interpretation. 2 ed. Baltimore, MD: Williams and Wilkins; 1973:121-7.
  53. Scotet V, Merour MC, Mercier AY, Chanu B, Le Faou T, Raguenes O, Le Gac G, Mura C, Nousbaum JB, Ferec C. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol. 2003;158:129–34. [PubMed: 12851225]
  54. Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol. 2010;105:610–2. [PubMed: 20203642]
  55. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855–61. [PubMed: 15256427]
  56. Stuhrmann M, Gabriel H, Keeney S. Clinical utility gene card for: Haemochromatosis. Eur J Hum Genet. 2010;18 [HFE] [PMC free article: PMC2987432] [PubMed: 20125190] [Cross Ref]
  57. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology. 2001;33:1321–8. [PubMed: 11343262]
  58. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006;145:209–23. [PubMed: 16880463]
  59. Whittington CA, Kowdley KV. Review article: haemochromatosis. Aliment Pharmacol Ther. 2002;16:1963–75. [PubMed: 12452931]
  60. Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol Hepatol. 2003;1:388–91. [PubMed: 15017658]
  61. Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology. 2007;133:489–95. [PubMed: 17681170]

Chapter Notes

Author History

Robin L Bennett, MS (2000-present)
Kris V Kowdley, MD (2000-present)
Arno G Motulsky, MD (2000-present)
Jonathan F Tait, MD, PhD; University of Washington School of Medicine (2000-2011)

Revision History

  • 19 April 2012 (me) Comprehensive update posted live
  • 4 December 2006 (me) Comprehensive update posted to live Web site
  • 13 July 2005 (kk) Revision: sequence analysis of entire coding region clinically available
  • 13 September 2004 (kk) Author revisions
  • 7 October 2003 (me) Comprehensive update posted to live Web site
  • 3 April 2000 (me) Review posted to live Web site
  • October 1998 (kk) Original submission
Copyright © 1993-2015, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK1440PMID: 20301613
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Tests in GTR by Gene

Tests in GTR by Condition

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed
  • Gene
    Gene records cited in chapters on the NCBI bookshelf. Links are provided by the authors or the NCBI Bookshelf staff.

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...